Edited and reviewed by: Haidong Wei, The Second Affiliated Hospital of Xi'an Jiaotong University, China
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the published article, a section of text was mistakenly not included in the publication. The missing section appears below:
The conditioned media for neurodifferentiation consisted of Neurobasal (Gibco) supplemented with GlutaMAX, N2, and B27 supplements (0.5% each, Gibco), penicillin-streptomycin (Gibco), and brain-derived neurotrophic factor (BDNF) (20 ng/mL, Wako), glia-derived neurotrophic factor (GDNF) (20 ng/mL, Wako), neurotrophin-3 (NT3) (10 ng/mL, Wako), insulin-like growth factor 1 (IGF-1) (20 ng/mL, PEPROTECH), and basic fibroblast growth factor (bFGF) (20 ng/mL, Wako). Monocyte-derived macrophages were treated with the following chemical compounds: CHIR99021, 3 μM; Forskolin, 10 μM; Y-27632, 5 μM; Dorsomorphin, 2 μM; ISX-9, 3 μM; DB2313, 0.5 μM.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.